GSK Moves Closer to a Hepatitis B Breakthrough in China

A functional cure for hepatitis B has long been the industry’s white whale. Now, GSK plc may be getting closer. The company announced that China’s regulator—the National Medical Products Administration, has accepted its New Drug Application (NDA) for bepirovirsen, an investigational therapy targeting chronic hepatitis B (CHB).

Why This Matters: A Massive Unmet Need?

Chronic hepatitis B isn’t a niche disease. It’s a global burden.

The scale:

• 250+ million people affected worldwide
• ~75 million in China alone
• ~450,000 deaths annually in China

Current treatments—mainly nucleos(t)ide analogues—do one thing well: suppress the virus.

What they don’t do:

• Deliver a functional cure
• Eliminate the need for lifelong therapy

Functional cure rates today? Roughly ~1%. That’s the gap bepirovirsen is trying to close.

What Is Bepirovirsen?

Bepirovirsen is not a typical antiviral. It’s an antisense oligonucleotide (ASO), a precision therapy designed to target the virus at the genetic level.

How it works:

• Targets HBV mRNA and pregenomic RNA
• Blocks viral replication
• Reduces HBsAg (surface antigen) levels
• Helps the immune system regain control

Translation: Instead of suppressing the virus, it aims to reset the system.

The Clinical Data: A Step Change

The NDA is backed by Phase III data from the B-Well 1 and B-Well 2 trials.

Key outcomes:

• Statistically significant functional cure rates
• Superior results vs. standard of care alone
• Stronger response in patients with lower baseline HBsAg levels
• Acceptable safety and tolerability profile

These were:

• Global, multi-centre trials
• Conducted across 29 countries
• Randomised, double-blind, placebo-controlled

That’s the gold standard for late-stage validation.

Regulatory Momentum Is Building

Bepirovirsen isn’t just another pipeline asset—it’s being fast-tracked globally.

Designations:

• Breakthrough Therapy: China
• Fast Track: U.S. Food and Drug Administration
• SENKU: Japan

These are reserved for therapies with the potential to meaningfully outperform existing options.

Strategic Angle: More Than a Single Drug

GSK isn’t positioning bepirovirsen as a standalone product. Instead, it could become a “backbone therapy” for future treatment combinations.

Why that matters:

• Hepatitis B is complex and persistent
• Combination therapies are likely needed for broader cures
• A backbone drug creates platform-level value

This is similar to how HIV treatment evolved—from monotherapy to combination regimens.

The China Focus: A Deliberate Move

Launching first in China is strategic.

• Largest addressable patient pool
• High disease burden
• Increasing regulatory efficiency

Approval here could:

• Validate the therapy at scale
• Accelerate global adoption

The Risk: Still Not Approved

Despite strong data, one fact remains:

Bepirovirsen is not yet approved anywhere in the world.

Key uncertainties:

• Regulatory review outcomes
• Real-world durability of functional cure
• Long-term safety in broader populations

Until approval, it remains a high-potential, high-stakes asset.

Final Take

This is one of the most important developments in hepatitis B in years.

• A new mechanism (ASO)
• A clear goal (functional cure)
• Late-stage clinical validation

If approved, bepirovirsen could shift hepatitis B treatment from lifelong management → finite therapy with durable control. And that’s a fundamental change in how the disease is treated.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!